Catalent to shutter Belgium cell therapy site, lay off workers

CDMO Catalent will close the doors to its ‘European Center of Excellence’ in Gosselies, Belgium, laying off 150 workers, according to local reporting.

The restructuring is reportedly due to a drop in production at the site, which serves as Catalent's European production hub. In 2022, Catalent completed construction of a 60,000-square-foot commercial production and fill-finish facility adjacent to the Gosselies facility acquired from Bone Therapeutics in 2020.

The news is the latest in several gene therapy-focused restructuring announcements from Catalent following the CDMO's $16.5 billion buyout by Novo Holdings in 2024. In August 2025, Catalent cut approximately 350 jobs across its gene therapy manufacturing operations in Maryland, attributing the cuts to “a sudden change in demand from a large customer.” A few months later in November 2025, Catalent confirmed another round of layoffs at its Baltimore operations.